Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction

Acta Neurologica Scandinavica

Volumn 108, Issue 2, 2003, Pages 109-113

  Petrovič, Danijel ^a,d   Milanez, T ^b   Kobal, J ^b   Bregar, D ^a   Potisk, K P ^c   Peterlin, B ^b  

^a Medical Faculty of Ljubljana   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY REHABILITATION INSTITUTE   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

4G 5G PAI 1 gene promoter polymorphism; Atherothrombotic stroke; Factor VII Arg Gln353 gene polymorphism; G1691A factor V point mutation; Risk factors

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE INSERTION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; OCCLUSIVE CEREBROVASCULAR DISEASE; POINT MUTATION; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS;

AGED; CASE-CONTROL STUDIES; CEREBRAL INFARCTION; FACTOR V; FACTOR VII; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POINT MUTATION; POLYMORPHISM, GENETIC; RISK FACTORS; SLOVENIA;

EID: 0043171091     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00126.x     Document Type: Article

References (32)

1. MARTI-VILALTA JL, ARBOIX A. The Barcelona Stroke Registry. Eur Neurol 1999;41:135-42.
2. KANNEL WB, MCGEE DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-8.
3. MACMAHON S, PETO R, CUTLER J et al. Blood pressure, stroke, and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
4. STEGMAYR B, ASPLUND K, KUULASMAA K, RAJAKANGAS AM, THORVALDSEN P, TUOMILEHTO J. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project: an ecological study of 18 populations. Stroke 1997;28:1367-74.
5. JOHANSSON L, JANSSON JH, BOMAN K, NILSSON TK, STEGMAYR B, HALLMANS G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000;31:26-32.
6. CATTO AJ, CARTER AM, STICKLAND MH, BAMFORD JM, DAMES JA, GRANT PJ. Plasminogen activator inhibitor -1 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997;77: 730-4.
7. ERIKSSON P, KALLIN B, VAN'T HOOFT FM, BAVENHOLM P, HAMSTEN A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-5.
8. STEGNAR M, UHRIN P, PETERNEL P et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998;79:975-9.
9. HENRY M, TREGOUËT DA, ALESSI MC et al. metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations. A family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 1998;18:84-91.
10. ENDLER G, LALOUSCHEK W, EXNER M, MITTERBAUER G, HARING D, MANNHALTER C. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 2000;110:469-71.
11. ROEST M, VAN DER SCHOUW YT, BANGA JD et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000;101:67-70.
12. BERTINA RM, KOELEMAN BPC, KOSTER T et al. Mutation in blood coagulation factor V is associated with resistance to activated protein C. Nature 1994;369:64-7.
13. RIDKER PM, HENNEKENS CH, LINDPAINTER K, STAMPFER MJ, EISENBERG PR, MILETICH JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and deep venous thrombosis in apparently healthy men. New Engl J Med 1995;332:912-7.
14. FISHER M, FERNANDEZ JA, AMERISO SF et al. Activated protein C resistance in ischemic stroke not due to factor V arginine506-glutamine mutation. Stroke 1996;27: 1163-6.
15. KENET G, SADETZKI S, MURAD H et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000;31:1283-8.
16. VOETSCH B, DAMASCENO BP, CAMARGO EC et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000;83:229-33.
17. WEIH M, JUNGE-HULSING J, MEHRAEIN S, ZIEMER S, EINHAUPL KM. Hereditary thrombophilia with ischemic stroke and sinus thrombosis. Diagnosis, therapy and meta-analysis. Nervenarzt 2000;71:936-45.
18. GREEN F, KELLHER C, WILKES H, TEMPLE A, MEADE T, HUMPHRIES S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991;11:540-6.
19. LANE A, CRUICKSHANK JK, MITCHELL J, HENDERSON A, HUMPHRIES S, GREEN F. Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at different risk of coronary heart disease. Atherosclerosis 1992;94:43-50.
20. HEYWOOD DM, CARTER AM, CATTO AJ, BAMFORD JM, GRANT PJ. Polymorphisms of the factor VII gene and circulating FVII. C levels in relation to acute cerebrovascular disease and poststroke mortality. Stroke 1997;28:816-21.
21. KARIO K, MATSUO M, MIYATA T. Are there any associations among coagulation factor VII gene polymorphism, plasma activated factor VII levels, and cerebrovascular disease? Circulation 2000;101:E48.
22. NISHIUMA S, KARIO K, NAKANISHI K et al. Factor VII R353Q polymorphism and lacunar stroke in Japanese hypertensive patients and normotensive controls. Blood Coagul Fibrinolysis 1997;8:525-30.
23. WORLD HEALTH ORGANIZATION DIABETES MELLITUS. Report of a WHO study group. WHO Tech Rep Ser;727:9-10, 1985.
24. MANSFIELD MW, STICKLAND MH, GRANT PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995;74:842-7.
25. MANNUCCI PM, MARI D, MERATI G et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins: a study in centenarians. Arterioscler Thromb Vasc Biol 1997;17:755-9.
26. BANG CO, PARK HK, AHN MY, SHIN HK, HWANG KY, HONG SY. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001;11:294-9.
27. RIDKER PM, HENNEKENS C, LINDPAINTNER K, STAMPFER MJ, MILETICH JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
28. YE S, GREEN FR, SCARABIN PY et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude Cas-Temoins L'infarctus Mycocarde Thromb Haemost 1995;74:837-41.
29. SHAH PK, FALK E, BADIMON JJ et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-9.
30. LALOUSCHEK W, AULL S, SERLES W et al. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. Thromb Res 1999;93:61-9.
31. 353 gene polymorphism on the risk of premature coronary artery disease. Ann Genet 2001;44:33-6.
32. EMMERICH J, AIACH M. Letter to the editor. Mutation in the factor V gene and the risk of myocardial infarction. New Engl J Med 1995;333:880-1.